News

Zacks.com on MSN22h
NTLA Stock Down as Patient Faces Adverse Event in Gene Therapy Study
Intellia stock tanks after a patient in its phase III study evaluating gene therapy candidate nex-z in ATTR-CM experiences serious liver enzyme elevation.
The Healthy @Reader's Digest on MSN16h
Is It Hives or a Rash? Here’s How to Tell the Difference
When your skin is red, itchy, and irritated, it could be a rash or it might be hives. We spoke with experts to learn how to ...
Precision Medicine Online20h
Intellia Reports Safety Event in Phase III Trial of Gene-Editing Drug for ATTR-CM
A patient participating in the Phase III MAGNITUDE trial of nex-z experienced asymptomatic grade 4 liver transaminase elevations, the firm reported.